Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.BioNTech, known for its partnership with Pfizer in developing the first COVID-19 vaccine in the US market, is expecting a return to revenue growth in 2025 after a sales slump of its COVID vaccine affected its bottom line. The company plans to raise prices on the COVID vaccine to maintain revenue while investing in its oncology pipeline for future gains. Meanwhile, Pfizer and Moderna, the other two COVID vaccine giants, are taking different approaches to post-pandemic growth.NeurVati Neurosciences, a blackstone life sciences-backed company, is focusing on later-stage assets to derisk development in neuroscience R&D. Despite recent setbacks in Alzheimer's and ALS drugs, pharma companies are urged to prioritize understanding the patient journey. Pharma companies are also exploring new ways to deliver gene therapies efficiently. Overall, the industry is adapting to evolving trends and challenges to drive innovation and growth in the life sciences field.